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1. Introduction 
Understanding and controlling the solid-state chemistry of active pharmaceutical 
ingredients (APIs) is an important aspect of drug development process. APIs can exist in a 
variety of distinct solid forms, including polymorphs, solvates, hydrates, salts, cocrystals 
and amorphous solids. Most APIs are purified and isolated by crystallization from an 
appropriate solvent during the final step in the synthetic process. A large number of factors 
can influence the crystal nucleation and growth during this process, including the 
composition of the crystallization medium and the processes used to generate 
supersaturation and promote crystallization. For development of a pharmaceutical product, 
it is generally accepted that the stable form should be identified and chosen for 
development. However, the stable crystal form of the parent compound may exhibit 
inadequate solubility or dissolution rate resulting in poor oral absorption, particularly for 
water insoluble compounds whereas a metastable form might have advantageous 
properties. Moreover, the metastable polymorphs constitute local minima in the energy 
landscape (Figure 1) with the thermodynamically stable form being the absolute minimum 
at a given temperature and pressure. Thus, the search for absolute minimum and energy 
differences between the local minima of the drug substances is the goal of material and 
formulation scientists in the pharmaceutical industry. While significant efforts are made by 
drug development groups to identify and characterize thermodynamically stable crystal 
forms early in development, there are many instances where new crystal forms have been 
discovered later in development process. The late emergence of thermodynamically stable 
crystal form is often explained by Ostwald’s law of stages which states that the least stable 
crystal form is likely to crystallize first. Metastable forms appear first during crystallization 
process as their crystallization kinetics is faster than those of stable forms but eventually 
transform into a stable form. It is important to study the transformations, because the 
sudden appearance or disappearance of a polymorphic form in pharmaceutical products can 
lead to serious consequences. 
Therefore, it is of utmost importance to control the crystal formation and produce a desired 
form. Discovery and characterization of the diversity of solid forms of a drug substance 
provide options from which to select a form that exhibits the appropriate balance of the 
critical properties for development into the drug product. Lately, the crystal engineering 
approaches utilizing high throughput techniques have been applied to crystalline materials 
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to fruitfully generate various crystal forms of pharmaceutical compounds. The ability to 
engineer pharmaceutical materials with suitable solubility characteristics whilst maintaining 
suitable physical and chemical stability provides a driving force to utilize modern analytical 
tools to generate new crystal modifications. 
Drugs with multicomponent crystalline phases such as cocrystals also carry desired drug 
properties similar to single-component polymorphs. The pharmaceutical cocrystals is 
defined as multicomponent molecular complex where one of the components is an 
investigational or marketed drug molecule (the active pharmaceutical ingredient or API) 
and the second component (the coformer) is a safe chemical for human consumption 
selected from the GRAS list of the US FDA (generally regarded as safe additive chemicals by 
the Food and Drugs Administration). The two components are present in a definite 
stoichiometric ratio and interact through noncovalent interactions, predominantly hydrogen 
bonds. Cocrystals have been found to offer an attractive platform to improve the solubility 
and dissolution rate of pharmaceuticals without compromising on the stability of the solid 
form. Many pharmaceutical companies are working actively on cocrystals and this is 
reflected by the growing number of publications and patent applications for co-crystals in 
recent years.  
 
Fig. 1. Energy landscape for polymorphic forms. 
The identification and characterization of diverse crystalline forms of the drug substances 
has become imperative for the solid state chemists in order to select the appropriate form 
to ensure that the product performance with respect to manufacturability, stability and 
bioavailability remains unchanged. Therefore, this chapter deals with the effect of 
crystalline state of pharmaceutical material on its physicochemical properties 
demonstrated through several case studies describing the phenomenon of polymorphism 
and a particular attention will also be paid to cocrystallization which is emerging as an 
important technique to generate crystal forms with improved physicochemical properties 
(Scheme 1).  
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Scheme 1. Scheme representing the path followed by drugs from nucleation to production  
1.1 Effect of crystal forms on physicochemical properties 
It is well established that different solid forms of drug molecules exist and can affect 
pharmaceutical drug products with respect to physicochemical properties. It is the variation 
in the physical and chemical properties of drug molecules that makes polymorphism such a 
potentially important issue for the pharmaceutical industry. The APIs with abundant 
hydrogen bond sites and molecular flexibility may be manipulated by proper choice of 
solvent to form a specific crystal form that has different arrangements or conformations of 
the molecule in the crystal lattice. Changing the arrangement of the molecules in the crystal 
lattice changes the solid state properties affecting its solubility, stability, dissolution rate and 
bioavailability. Different crystal forms can have different rates of uptake in the body, 
leading to lower or higher biological activity than desired. As a result, significant effort is 
placed in identifying suitable solid forms of drug substances for use in pharmaceutical drug 
products.  
1.2 Crystallization process 
The crystallization process of polymorphous crystals is concerned with evolution of 
crystalline state from solution or melts and is composed of competitive nucleation and 
growth. However, crystallization is a complex process which starts with the appearance of 
most soluble form and ends with transformation to stable form. Alternatively, the 
nucleation of the stable form can be initiated by the dissolution of this metastable form and 
growth of the stable form continues until the solubility of stable forms is reached. In many 
instances the metastable form with desirable properties may precipitate out which is stable 
for years. To selectively crystallize polymorphs, the mechanism of each elementary step in 
crystallization process needs to be clear in relation to operational conditions and the key 
controlling factors. The nucleation process is the most important for control of 
polymorphous crystallization. Thus control over solid form throughout the drug 
development process is of paramount importance. 
A number of factors (Figure 2) affect polymorphic behavior of a pharmaceutical solid and 
type of solvent has a major factor in polymorphic selectivity and crystal morphology.  
1.3 Effect of solvent on crystal form 
Polymorph selectivity is primarily based on the polarity of the solvent. Thus a systematic 
approach for selecting the right solvent is beneficial for better experimental design in control 
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of crystallization. This effect arises from the solvent–solute interaction at the molecular level 
and have been explained by few of the researchers. The solvent–solute interactions during 
cluster formation for nucleation and growth significantly affect the ultimate crystal structure 
and morphology. If the solvent–solute are strongly bonded at a special crystal face, the rate-
limiting step of growth would be the removal of the solvent from that face. In this case, the 
bonded surface grows slowly or does not grow. 
However, Threlfall showed that if crystallization occurs in a region that is supersaturated 
with respect to one polymorph (the less soluble form) and under-saturated with respect to 
the other one, the solvent has no influence on the nucleation of the polymorphs and the 
thermodynamics will lead the process toward the production of the less soluble polymorph 
(Threlfall T., 2000). Moreover, the thermodynamically stable polymorph is the most stable 
form irrespective of the type of the solvent used. Since the thermodynamic stability of 
different polymorphs does not change with type of the solvent, then the solvent effect on 
polymorphism is attributed to the kinetic parameters.  
 
Fig. 2. Factors which affect the crystallization of a drug substance 
1.4 Other factors 
Within the same solvent system, many factors are known to influence the crystal habit 
including supersaturation, cooling rate and agitation. At a constant temperature, 
supersaturation has a direct effect on the nucleation rate. As the supersaturation is 
increased, the rate of nuclei formation is greater than crystal growth and growth occurs 
mainly in one direction, producing elongated crystals. On the other hand, when there is 
lesser degree of supersaturation, solute solvent interactions are insignificant, producing 
platy crystals. 
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Similarly, rate of cooling alters the crystal habit by its influence on degree of supersaturation. 
Crystallization at a slower cooling rate produces more symmetric crystals compared with 
faster cooling. During faster cooling, nucleation is faster than crystal growth rate; therefore, 
many small crystals appear instead of few crystals growing to sufficiently larger size. 
Agitation has also an important effect on the process of crystallization. The aspect ratio 
(ratio of horizontal maximum and vertical maximum distance of particle) is highest for 
unstirred conditions than during stirring. The crystals obtained under stirring conditions are 
fine since stirring facilitates the rate of nucleation by an even distribution of the solute 
molecules in the solvent. Increased nucleation rate is the result of collision of initial crystals 
with the stirrer and formation of smaller seeds for further crystallization. Additionally, 
stirring can also break larger crystals to smaller ones. Thus external appearance of a crystal 
can be altered by changing the growth environment to suit the requirements.  
2. Polymorphism in anti-HIV drugs 
This chapter throws light on the different crystalline forms reported so far for nevirapine, 
efavirenz, lamivudine, stavudine and zidovudine. Preparation and isolation methods, 
structural characterization and properties of polymorphic/solvatomorphic/cocrystal 
systems as well as phase transformations are illustrated. 
2.1 Ritonavir 
A number of studies have successfully demonstrated the appearance of different crystalline 
forms of some anti-HIV drugs upon recrystallization. An early example being that of ritonavir, 
marketed as Norvir. The late emergence of a thermodynamically more stable form (Form II) 
which unexpectedly precipitated from the semisolid capsule formulation led to the removal of 
the product from the market. The new crystal form (form II) appeared after conversion of 
metastable crystalline form I (Chemburkar et al., 2000; Bauer et al., 2001; Desikan et al., 2005; 
Miller et al., 2005). Ritonavir polymorphism was investigated using solid state spectroscopy 
and microscopy techniques including solid state NMR, near infrared spectroscopy, powder X-
ray diffraction and single crystal X-ray analysis. Ritonavir was found to exhibit conformational 
polymorphism with two unique crystal lattices having significantly different solubility 
properties. An unusual conformation was found for form II that results in a strong hydrogen 
bonding network. Although the polymorph (form II) corresponding to the “cis” conformation 
has a more stable packing arrangement, however, nucleation, even in the presence of form II 
seeds, is energetically unfavored except in highly supersaturated solutions. The coincidence of 
a highly supersaturated solution and a probable heterogeneous nucleation resulted in the 
sudden appearance of the more stable form II polymorph.  
Form  Melting point, °C ∆Hfus, J/g Solid state structure 
I*  122 78.2 Monoclinic 
II*  122  87.8  Orthorhombic 
III  78–82  60.3  Monoclinic 
IV  116  59.8  Not assigned 
V  97  32.0  Monoclinic 
*Bauer et al. 
Table 1. Comparison of physical parameters of ritonavir crystal forms 
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This polymorphic shift in ritonavir illustrated the need for early and comprehensive 
identification of solid-form diversity of this API. The polymorphic behavior of ritonavir was 
explored by Morissette et al (Morissette et al., 2003) in 2003 using CrystalMax, a high-
throughput crystallization platform, with the aim of finding known and novel crystal forms 
of the drug molecule. Three additional crystalline forms of ritonavir were discovered when 
about 2,000 screening experiments were carried out (Table 1). These forms were found along 
with both known forms I and II, which were obtained from previously unreported solvent 
mixtures. Form III is a crystalline formamide solvate that converts to form V, a previously 
unknown hydrated phase, upon exposure to aqueous medium. Form V which is a trihydrate 
obtained from exposing the form III to aqueous conditions, in turn converts spontaneously 
to needle-like form I crystals. The process of preparing form I from III is an unusual route to 
a ‘‘disappearing polymorph’’ and provides a novel strategy for control of particle size and 
morphology. Form IV is a true, unsolvated, metastable previously unreported polymorph of 
ritonavir. Optical imaging (Figure 3) and in situ Raman spectroscopy were used to 
characterize newly formed crystals. Each of the novel forms found by means of high-
throughput crystallization was scaled up to multiple milligram and gram levels. Thus the 
high-throughput crystallization for solid-form discovery and exploration of large numbers 
of parallel crystallization trials led to identification of more polymorphic forms of ritonavir. 
 
Fig. 3. Video micrograph of crystal Form I (left) and Form II (right).  
2.2 Nevirapine 
Three polymorphs and many solvatomorphs have been reported for nevirapine, a non-
nucleoside reverse transcriptase inhibitor, depending upon the recrystallization method. 
Specifically, from a crystal engineering viewpoint, the presence of the amide function CO-
NH in the nevirapine molecule indicates the possibility of alternative modes of self 
association, namely via a dimer or a catemer synthon, leading to crystal polymorphism, 
whereas interaction with the solvent molecules having complementary donor and acceptor 
functions result in formation of solvates, significantly extending the solid state chemistry of 
the drug. Form I was prepared by recrystallizing nevirapine from alcohols, ethers, esters or 
their mixtures while refluxing from toluene, n-butanol or methyl-isobutyl ketone and 
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subsequent cooling to 0-10 ºC yielded form II. Form III was prepared by refluxing 
nevirapine in chloroform and using dichloromethane as antisolvent to the reaction mixture 
(Reguri and Chakka, 2005, 2006). However, many other experiments to investigate the 
existence of any other thermodynamically more stable form at room temperature, led to 
appearance of different solvatomorphs of nevirapine with varying stoichiometries 
depending upon the solvents selected. The first report on preparation of different 
solvatomorph by Pereira et al appeared in 2007 (Pereira et al., 2007). Six different solvates of 
nevirapine with different morphology were obtained by saturating the solvent systems with 
drug at room temperature and cooling in refrigerator. Despite different morphologies the 
DSC profiles did not show any relevant differences for raw material and other forms at 
crystal fusion peaks. However, a thermal event was observed below the melting 
temperature in NEV 3, NEV4 and NEV6 indicating the loss of some solvent molecules. The 
presence of solvent is confirmed by TGA and Karl fischer analysis. The authors have 
reported the crystal structure of two solvate forms of nevirapine, hemihydrate (NEV3) and 
hemiethylacetate (NEV4) (Figure 4).  
 
Fig. 4. Ortep representation of structure of (a) nevirapine hemihydrate and (b) nevirapine 
hemiethyl acetate solvate.  
Caira et al have also reported five different solvates of nevirapine (Caira et al., 2008). The 
initial characterization of all the forms has been performed utilizing DSC and TGA. The 
results show that the drug molecule displays significant variability in its modes of self 
assembly while accommodating the different solvent molecules. The DSC results show less 
thermal stability for toluene solvate while ethylacetate solvate, dichloromethane solvate, 
hydrate and 1,4-dioxane solvate were stable. The ethylacetate solvate and dichloromethane 
solvate are isostructural and their dimmers are packed in identical fashion, generating 
continuous channels parallel to the b-axis that accommodate the solvent molecules (Figure 
5). However, in the toluene solvate containing a larger guest molecule, the host dimers are 
packed in a different mode, but the guest molecules are again situated in channels.  
The effect of series of alcohols on solvate formation capability of nevirapine molecule has 
also been illustrated by Caira et al (Caira et al., 2010). The structures of all the solvates were 
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based on a common isostructural framework comprising centrosymmetric hydrogen-
bonded nevirapine dimers and contain a common channel parallel to the crystal b-axis in 
the series which accommodates the various solvent molecules. Thermogravimetric results 
yielded a guest–host ratio close to 0.5 for the 1-butanol solvate and a steady decrease in this 
ratio from 0.43 to 0.32 for other solvates. This anomalous stoichiometric variation was 
resolved following successful X-ray analysis of 1-butanol solvate which revealed that the 
length of disordered 1-butanol molecule is proportionate with the channel cavity, resulting 
in a stoichiometric association while in other solvates significant disorder for the solvent 
molecules was observed which is attributed to their increasing chain lengths being 
disproportionate with the channel cavity. 
 
Fig. 5. Inclusion of ethyl acetate molecules within channels in crystals of solvate of 
nevirapine.  
In the view of tendency of solvate formation of nevirapine molecule, other workers have 
also prepared and characterized the various solvates of nevirapine. In one of the studies, the 
authors have prepared the solvates by dissolving excess drug in selected solvent systems at 
60 ºC. However, the choice of solvent system was based on the polarity index of the solvents 
(Sarkar et al., 2008). Five different crystal forms have been obtained along with an 
amorphous form. The crystallization of nevirapine under a variety of crystallization 
conditions resulted in a change in the crystal habit of the drug without change in the 
internal crystal lattice as suggested by their similar enthalpy of fusion. The mass loss from 
the TGA was found to be negligible for all the solvates in comparison to the theoretical mass 
loss indicating that solvents used for crystallization formed weak solvates in this study. 
However, chadha et al have determined the binding energy of the solvent in the crystal 
lattice using differential scanning calorimetry which is found to be higher than the enthalpy 
of vapourization of the corresponding solvent for all the solvates except for toluene solvate 
indicating that the solvent molecules are tightly bound into the crystal lattice of nevirapine 
molecule (except in case of toluene solvate) (Chadha et al., 2010). These authors have also 
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calculated the enthalpy of solvation by determining enthalpy of solution of solvate and drug 
in the solvent which is entrapped in the crystal lattice of the solvate using solution 
calorimetry technique. The enthalpy of solution when determined in buffer system indicated 
that out of the six solvates formed ethanol solvate exhibited the maximum ease for 
molecular release of the solvent molecule from the lattice.  
2.3 Efavirenz 
The abundant hydrogen bonding sites in efavirenz, another non-nucleoside reverse 
transcriptase inhibitor, make it a potential candidate to exhibit crystal modifications upon 
recrystallization. Driven by this aspect, various authors investigated the solid-state 
structures of recrystallized products of efavirenz. The varying recystallization conditions 
such as rate of stirring and cooling, antisolvent addition, refluxing/heating, drying under 
vacuum, and presence of impurities, along with solvents and/or their mixtures with 
varying polarity have yielded different forms of efavirenz. The patent literature till date 
reveals 23 different polymorphic forms of efavirenz, one monohydrate and an amorphous 
form although there is some ambiguity about the actual number of solid forms (polymorphs 
and solvates) of this API (Radesca et al., 1999, 2004; Sharma et al., 2006; Khanduri et al., 
2006; Reddy et al., 2006; Dova, 2008). In these patents, inventors have claimed novel solid 
forms of efavirenz based on XRPD and DSC analysis. The patent data shows that Form I is 
the most stable form and all the polymorphs revert to this form under some condition or the 
other. However, the characterization of these reported forms is not adequate enough to 
prove them novel. 
 
Fig. 6. Solid forms of efavirenz, their transformations and some synthons present in the 
polymorphs of efavirenz 
Recently, two new polymorphc forms structurally characterized by single crystal X-ray 
diffraction have been reported by Cuffini et al and Ravikumar et al (Cuffini et al., 2009; 
Ravikumar et al., 2009). These two forms do not correspond to the Form I reported in 
various patent.  
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Fig. 7. Efavirenz, form I: (a) A view of the double helical chain viewed down the c-axis with 
the three symmetry independent molecules represented in red, green, and blue. The inset 
shows the formation of the double helical chains. (b) Hexagonal close packing of helices. (c) 
PXRD pattern for form 18g and form I. (d) DSC trace for form I. 
The structural information of the stable Form I was first reported by Mahapatra et al 
(Mahapatra et al., 2010). The authors obtained this form (Form I) at the interface of an 
acetonitrile-water solvent system as well as from methylcyanide-water mixture (Figure 6). 
They also reported a solvate of efavirenz which was obtained by dissolving the drug in 
cyclohexane at 60 ºC with stirring and leaving the solution undisturbed for 2 days after 
filtration to get rectangular crystals. The DSC analysis of these two forms showed that the 
solvate converts to Form I after desolvation. Both the forms have been further characterized 
using single crystal X-ray analysis. The efavirenz molecule exhibits a noticeable degree of 
conformational disorder in the cyclopropyl group. After exhaustive study it was found that 
Form I crystallized in double stranded helices stabilized by N-H···O molecules (Figure 7). 
However, in the solvate, two molecules of efavirenz form the amide dimer which are 
stabilized by C-H···π interactions to form a bilayer stacked in three dimensions to form 
columns. The solvent molecules are lined in these columns and are stabilized by interactions 
with CF3 and cyclopropyl residues (Figure 8).  
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Fig. 8. (a) Crystal packing of efavirenz with the guest cyclohexane molecules represented in 
the space filling mode (b) HSM images of II (corresponding temperatures are given in 
parentheses)(c) PXRD patterns of forms I and II and the heated sample of form II (d) DSC 
plot for form II. 
2.4 Lamivudine 
Further studies on these categories of drugs have shown the existence of different crystal 
forms of lamivudine which is a nucleoside analog reverse transcriptase inhibitor. The solid 
state chemistry of this drug is of significant pharmaceutical interest as the drug is reported 
to exist in three crystalline forms. The two forms (Form I and II) reported in 1996 were again 
studied by Harris et al in 1997 (Jozwiakowski et al., 1996; Harris et al., 1997). Later in 2007, a 
new patent showing the existence of another polymorphic form III appeared (Singh et al., 
2007). Michael et al have shown that Form I of lamivudine has been prepared by dissolving 
Form II in hot water and then adding an equal volume of methanol to reduce the solubility 
of lamivudine. The Form II has been obtained as a result of a synthetic process. The DSC 
studies showed heat mediated transformation of Form I to Form II. Besides this, these 
authors have also calculated the enthalpy of solution from solubility data and compared the 
results with experimently determined enthalpy of solution by solution calorimetry 
technique. The enthalpy data revealed that the enthalpy of solution value agrees more 
closely in systems of low solubility than in system with high solubility.  
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Harris et al have recrystallized form I of lamivudine as needles from solutions in water, 
methanol or aqueous alcohols while form II as tetragonal bipyramids on slow recrystallization 
from dry ethanol and propanol or mixtures of ethanol and less polar organic solvents (Figure 
9). Probably, the difference in the polarity of organic solvents led to two different crystalline 
forms. The authors have used cross-polarization magic angle spinning (CPMAS) NMR to 
differentiate the two forms. The Form II showed a simple spectrum indicating one molecule in 
the crystallographic asymmetric unit whereas the spectrum of Form I was found to be 
extremely complex due to differences in intermolecular packing environment or 
intramolecular geometry/conformation differences. These results were further confirmed by 
single crystal X-ray analysis. The Form II was bipyramidal crystals with one molecule in the 
asymmetric unit and Form I showed five molecules in the asymmetric unit of crystal lattice. 
The crystals of Form III are obtained by subjecting the hot saturated solution of lamivudine 
in water to controlled cooling. The DSC and TGA showed this form to be different from 
Form I and II. The single crystal X-ray diffraction reveals it to be a hemihydrates with two 
molecules of water associated with four molecules of lamivudine in a crystal lattice.  
 
Fig. 9. Scanning electron micrographs of the two forms of Lamivudine 
2.5 Stavudine 
Stavudine, a thymidine nucleoside reverse transcriptase inhibitor, has been reported to exist 
in two anhydrous polymorphic forms and one hydrate. Harte et al and Guruskaya et al have 
reported the single crystal of Form I and Form II respectively (Harte et al., 1991 as sited in 
Gandhi et al., 2000; Guruskaya et al., 1991 as sited in Gandhi et al., 2000). However, the 
production of pure Form I i.,s reported by Gandhi et al who have established the conditions 
of recrystallization governing the formation of this thermodynamically most stable form 
(Gandhi et al., 2000). The stavudine obtained during the synthesis process is recrystallized 
from hot organic solvents as the final step in the synthesis. The cooling of hot isopropanol 
solution from 80 to 70 ºC for over an hour and then to 0-5 ºC over 1.5 h yielded a mixture of 
Form I and II. However, Form I was found to be thermodynamically more stable. Therefore, 
some of the crystallization parameters such as rate of cooling or stirring were studied during 
recrystallization from isopropanol to selectively obtain Form I. After a lot of 
experimentation, it was found that slow cooling of hot isopropanol solution reproducibly 
yielded Form I. Kinetically both forms may be present initially but Form II redissolves and 
precipitates as Form I with slow cooling.  
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2.6 Cocrystals 
Recently, cocrystallization has emerged as an attractive technique to recrystallize molecular 
solids that contain two or more distinct chemical components held together by non-covalent 
interactions. Anti-HIV agents have also been explored by this approach. The cocrystals of 
efavirenz with 4,4’-bipyridyl and 1,4-cyclohexanedione prepared by recrystallization of their 
grounded mixture from THF and from a mixture of n-heptane and THF respectively have 
been reported by Mahapatra et al (Mahapatra et al., 2010). Similarly, the multiple hydrogen 
bond donor and acceptor groups of lamivudine and zidovudine have been utilized by Bhatt 
et al for designing their cocrystals (Bhatt et al., 2009). These authors have designed 
zidovudine cocrystal using retrosynthetic approach where two drug molecules and one 
molecule of 2,4,6-triaminopyrimidine are held together by a three point synthon which 
forms basic part of their cocrystal structure (Figure 10).  
Besides this, a cocrystal hydrate of lamivudine with zidovudine has been reported. 
Lamivudine and zidovudine molecules are expected to form synthon II with each other as 
shown in figure 11. However, during cocrystallization a hydrated 1:1 cocrystal is formed 
and the synthon formed is the extended IIA synthon rather than II. The observed synthon 
(IIA) is formed when a molecule of water intervenes in the hydrogen bond pattern of the 
synthon II. The cocrystallization without use of water resulted in no cocrystal formation in 
this case, perhaps due to the large repulsions between the carbonyl groups in the two API 
fragments (Figure 12).  
 
Fig. 10. Three-point synthon I and possibility of this synthon between zidovudine and 2,4,6-
triaminopyrimidine 
 
Fig. 11. Predicted two-point synthon II between lamivudine and zidovudine and observed 
synthon IIa in the hydrated co-crystal  
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Fig. 12. Possible carbonyl - carbonyl repulsion in the putative lamivudine-zidovudine co-
crystal with non-hydrated synthon II  
Another cocrystal of lamivudine is designed and prepared with 3,5-dinitrosalicylic acid 
based upon synthon containing carboxylic acids and 2-aminopyridines. This cocrystal is an 
example of acid base interaction with a very complex hydrogen bond pattern. These authors 
also reported cocrystal of lamivudine with 4-quinolinone in a stoichiometry of 1:1. This 
cocrystal is stabilized by multiple N-H···O and O-H··· O hydrogen bonds. This cocrystal is 
obtained during the screening process and is not based on any synthon theory. Thus the 
lamivudine-4-quinolinone cocrystal emphasizes the importance of cocrystal screening to 
obtain new cocrystals rather than completely depending on the synthon theory. 
 
Fig. 13. Cocrystals of efavirenz and their preparation 
The possible formation of cocrystals of efavirenz with 1,4-cyclohexanedione and 4,4’-
bipyridyl was indicated by X-ray diffraction analysis (Mahapatra et al., 2010). The solids 
obtained from solvent drop grinding experiment, were subjected to recrystallization in 
particular solvent systems (Figure 13). Crystals of efavirenz-1,4-cyclohexanedione were 
obtained from heptane-THF solution. These crystals exhibited two symmetry independent 
dione molecules in a skewed conformation. One of these two dione molecules makes 
bifurcated N-H···O/C-H···O hydrogen bonds with two symmetry related molecules of 
efavirenz, forming a three molecular entity, while the other dione molecule makes linear 
chains with bifurcated C-H…O hydrogen bonds. These two patterns stacked over one 
another to form grill-ribbon structure of the cocrystal (Figure 14).  
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Fig. 14. Cocrystal of efavirenz and 1,4-cyclohexanedione: crystal packing along with the 
conformation in the native dione crystal (green). 
The cocrystal of efavirenz with 4,4’-bipyridyl was obtained by recrystallization from 
acetonitrile. Unlike the cocrystal with yclohexanedione in which the major synthon couldnot 
be anticipated, in this cocrystal two distinct heterosynthons were observed. While one of the 
efavirenz molecules interacted with bipyridyl through cyclic N-H···N/C-H··O hydrogen 
bonds, the other end of pyridine compound made a single point N-H···N hydrogen bond 
with other molecule of efavirenz resulting in pillered assemblies separated by hydrophobic 
cyclopropyl residues (Figure 15). 
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Fig. 15. Crystal packing.of efavirenz- 4,4’-bipyridyl cocrystal  
From the above examples it is clear that solvent recrystallization method has been the most 
common technique to prepare different crystal forms of a compound. However, with 
increasing demands to accelerate the process of crystal form identification, newer and 
advanced technologies need to be used as is exemplified by the isolation of three more 
polymorphic forms of ritonavir by high-throughput crystallization. In addition, 
cocrystallization technique has also been employing solution based crystallization methods 
to generate cocrystals of various pharmaceutical compounds. The studies on anti-HIV 
agents cited here are thus not simply academic exercises but have practical implications in 
preparation and identification of diverse crystalline forms of pharmaceutical material and 
can be of considerable benefit in formulation optimization.  
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